Phenotyping sarcoidosis from a pulmonary perspective

American Journal of Respiratory and Critical Care Medicine

Volumn 177, Issue 3, 2008, Pages 330-336

  Prasse, Antje ^a   Katic, Christine ^a   Germann, Martin ^a   Buchwald, Armin ^a   Zissel, Gernot ^a   Müller Quernheim, Joachim ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Chest X ray type; Classification; Phenotyping; Sarcoidosis; Treatment

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 2 RECEPTOR; NEOPTERIN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; FEMALE; GENETIC MARKER; HUMAN; HUMAN CELL; LONG TERM CARE; LUNG FUNCTION TEST; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; SARCOIDOSIS; THORAX RADIOGRAPHY;

ACUTE DISEASE; ADULT; BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE FLUID; COHORT STUDIES; FEMALE; HUMANS; LUNG; MIDDLE AGED; NEOPTERIN; PHENOTYPE; RECEPTORS, INTERLEUKIN-2; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SARCOIDOSIS, PULMONARY; SEVERITY OF ILLNESS INDEX;

EID: 38849093744     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200705-742OC     Document Type: Article

References (42)

1. Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H Jr, Bresnitz EA, DePalo L, Hunninghake G, Iannuzzi MC, Johns CJ, et al.; Case Control Etiologic Study of Sarcoidosis (ACCESS) Research Group. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001;164:1885-1889.
2. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997;336:1224-1234.
3. Müller-Quernheim J. Sarcoidosis: immunopathogenetic concepts and their clinical application. Eur Respir J 1998;12:716-738.
4. Baughman RP, Judson MA, Teirstein AS, Yeager H, Rossman MD, Knatterud GL, Thompson B. Presenting characteristics as predictors of duration of treatment in sarcoidosis. Q J Med 2006;99:307-315.
5. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003;361:1111-1118.
6. Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, Eklund A, Kitaichi M, Lynch J, Rizzato G, et al.; American Thoracic Society; European Respiratory Society; World Association of Sarcoidosis and Other Granulomatous Disorders. ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:149-173.
7. Löfgren S. Primary pulmonary sarcoidosis. I. Early signs and symptoms. Acta Med Scand 1953;145:424-431.
8. Löfgren S. Primary pulmonary sarcoidosis. II. Clinical course and prognosis. Acta Med Scand 1953;145:465-474.
9. Baughman RP, Lower EE. The variability of sarcoidosis: can we predict it? Chest 2003;123:1329-1332.
10. Sato H, Grutters JC, Pantelidis P, Mizzon AN, Ahmad T, Van Houte AJ, Lammers JW, Van Den Bosch JM, Welsh KI, Du Bois RM. HLA-DQB1*0201: a marker for good prognosis in British and Dutch-patients with sarcoidosis. Am J Respir Cell Mol Biol 2002;27:406-412.
11. Seitzer U, Gerdes J, Müller-Quernheim J. Evidence for disease phenotype associated haplotypes (DR.TNF) in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001;18:279-283.
12. Berlin M, Fogdell-Hahn A, Olerup O, Eklund A, Grunewald J. HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 1997;156:1601-1605.
13. Xing C, Gray-McGuire C, Kelly JA, Garriott P, Bukulmez H, Harley JB, Olsen JM. Genetic linkage of systemic lupus erythematosus to 13q32 in African American families with affected male members. Hum Genet 2005;118:309-321.
14. Altmuller J, Seidel C, Lee YA, Loesgen S, Bulle D, Friedrichs F, Jellouschek H, Kelber J, Keller A, Schuster A, et al. Phenotypic and genetic heterogeneity in a genome-wide linkage study of asthma families. BMC Pulm Med 2005;5:1.
15. Baughman RP, Lower EE. Treatment of sarcoidosis with corticosteroids: who is going to relapse and why? Sarcoidosis 1998;15:19-20.
16. Grunewald J, Eklund A. Sex-specific manifestations of Löfgren's syndrome. Am J Respir Crit Care Med 2007;175:40-44.
17. Spagnolo P, Renzoni EA, Wells AU, Sato H, Grutters JC, Sestini P, Abdallah A, Gramiccioni E, Ruven HJ, du Bois RM, et al. CC chemokine receptor 2 and sarcoidosis: association with Löfgren's syndrome. Am J Respir Crit Care Med 2003;168:1162-1166.
18. Valentonyte R, Hampe J, Croucher PJ, Müller-Quernheim J, Schwinger E, Schreiber S, Schürmann M. Study of CC chemokine receptor 2 alleles in sarcoidosis, with emphasis on family-based analysis. Am J Respir Crit Care Med 2005;171:1136-1141.
19. Scadding JG. Prognosis of intrathoracic sarcoidosis in England: a review of 136 cases after five years' observation. BMJ 1961;2:1165-1172.
20. Prasse A, Katic C, Germann M, Zissel G, Müller-Quernheim J. Phenotyping sarcoidoisis. Abstract presented at the Annual Congress of the European Respiratory Society. Eur Respir J 2006;28(Suppl 50);111s.
21. DeRemee RA. The roentgenographic staging of sarcoidosis: historic and contemporary perspectives. Chest 1983;83:128-133.
22. + T cells. Clin Exp Immunol 2000;122:241-248.
23. du Bois RM, Goh N, McGrath D, Cullinan P. Is there a role for microorganisms in the pathogenesis of sarcoidosis? J Intern Med 2003;253:4-17.
24. Valentonyte R, Hampe J, Huse K, Rosenstiel P, Albrecht M, Stenzel A, Nagy M, Gaede KI, Franke A, Haesler R, et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet 2005;37:357-364.
25. Rybicki BA, Hirst K, Iyengar SK, Barnard JG, Judson MA, Rose CS, Donohue JF, Kavuru MS, Rabin DL, Rossman MD, et al. A sarcoidosis genetic linkage consortium: the Sarcoidosis Genetic Analysis (SAGA) study. Sarcoidosis Vasc Diffuse Lung Dis 2005;22:115-122.
26. Sugisaki K, Yamaguchi T, Nagai S, Ohmiti M, Takenaka S, Morimoto S, Ishihara M, Tachibana T, Tsuda T. Clinical characteristics of 195 Japanese sarcoidosis patients treated with oral corticosteroids. Sarcoidosis Vasc Diffuse Lung Dis 2003;20:222-226.
27. Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, Goldmann T, Vollmer E, Muller-Quernheim J, Zissel G. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med 2006;173:781-792.
28. Medinger AE, Khouri S, Rohatgi PK. Sarcoidosis: the value of exercise testing. Chest 2001;120:93-101.
29. Keogh BA, Crystal RG. Clinical significance of pulmonary function tests: pulmonary function testing in interstitial pulmonary disease. What does it tell us? Chest 1980;78:856-865.
30. Drent M, Jacobs JA, de Vries J, Lamers RJ, Liem IH, Wouters EF. Does the cellular bronchoalveolar lavage fluid profile reflect the severity of sarcoidosis? Eur Respir J 1999;13:1338-1344.
31. Drent M, van Velzen-Blad H, Diamant M, Hoogsteden HC, van den Bosch JM. Relationship between presentation of sarcoidosis and T lymphocyte profile: a study in bronchoalveolar lavage fluid. Chest 1993;104:795-800.
32. Ziegenhagen MW, Rothe ME, Schlaak M, Müller-Quernheim J. Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis. Eur Respir J 2003;21:407-413.
33. Hunninghake GW, Crystal RG. Pulmonary sarcoidosis:a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity. N Engl J Med 1981;305:429-434.
34. Verstraeten A, Demedts M, Verwilghen J, van den Eeckhout A, Marien G, Lacquet LM, Ceuppens JL. Predictive value of bronchoalveolar lavage in pulmonary sarcoidosis. Chest 1990;98:560-567.
35. Lawrence EC, Brousseau KP, Berger MB, Kurman CC, Marcon L, Nelson DL. Elevated concentrations of soluble interleukin-2 receptors in serum samples and bronchoalveolar lavage fluids in active sarcoidosis. Am Rev Respir Dis 1988;137:759-764.
36. Grutters JC, Fellrath JM, Mulder L, Janssen R, van den Bosch JM, van Velzen-Blad H. Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation. Chest 2003;124:186-195.
37. Müller-Quernheim J, Kronke M, Strausz J, Schykowski M, Ferlinz R. Interleukin-2 receptor gene expression by bronchoalveolar lavage lymphocytes in pulmonary sarcoidosis. Am Rev Respir Dis 1989;140:82-88.
38. Bitterlich G, Szabo G, Werner ER, Larcher C, Fuchs D, Hausen A, Reibnegger G, Schulz TF, Troppmair, WH, et al. Selective induction of mononuclear phagocytes to produce neopterin by interferons. Immunobiology 1988;176:228-235.
39. Homolka J, Lorenz J, Zuchold HD, Müller-Quernheim J. Evaluation of soluble CD14 and neopterin as serum parameters of the inflammatory activity of pulmonary sarcoidosis. Clin Investig 1992;70:909-916.
40. Müller-Quernheim J. Serum markers for the staging of disease activity of sarcoidosis and other interstitial lung diseases of unknown etiology. Sarcoidosis Vasc Diffuse Lung Dis 1998;15:22-37.
41. Sharma P, Smith I, Sharma P, Smith I, Maguire G, Stewart S, Shneerson J, Brown MJ. Clinical value of ACE genotyping in diagnosis of sarcoidosis. Lancet 1997;349:1602-1603.
42. Biller H, Zissel G, Ruprecht B, Nauck M, Busse Grawitz A, Müller-Quernheim J. Genotype-corrected reference values for serum angiotensin-converting enzyme. Eur Respir J 2006;28:1085-1090.